<DOC>
	<DOCNO>NCT02248090</DOCNO>
	<brief_summary>This phase 1 open label multicentre study AZD9496 administer orally patient advance ER+ HER2 negative breast cancer . The study design allow escalation dose intensive safety monitoring ensure safety patient . The study determine maximum tolerate dose . In addition , expansion cohort ( ) potential therapeutic dose ( ) patient without ESR1 mutation enrol determine safety , tolerability , pharmacokinetics biological activity AZD9496</brief_summary>
	<brief_title>AZD9496 First Time Patients Ascending Dose Study</brief_title>
	<detailed_description>A Phase I , Open-Label , Multicentre Study Assess Safety , Tolerability , Pharmacokinetics Preliminary Anti-tumour Activity Ascending Doses AZD9496 Women Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Provision sign date , write informed consent prior mandatory study specific procedure , sample analysis . Aged least 18 year . Any menopausal status . Pre perimenopausal woman must commence treatment LHRH agonist least 4 week prior start study treatment must willing continue receive LHRH agonist therapy duration trial . Histological cytological confirmation adenocarcinoma breast . ERpositive accord local laboratory ; HER2 negative . Metastatic disease locoregionally recurrent disease amenable treatment curative intent . Disease progression least 6 month endocrine therapy ER+ breast cancer . Radiological objective evidence progression last systemic therapy prior start study treatment . Receipt â‰¤2 line prior chemotherapy advanced disease . Females childbearing potential must agree use adequate contraceptive measure , must breast feeding must negative pregnancy test prior start dose . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 deterioration previous 2 week minimum life expectancy 12 week . Any cytotoxic chemotherapy , investigational agent anticancer drug treatment advance breast cancer previous treatment regimen clinical study within 14 day first dose study treatment . Any unresolved toxicity prior therapy great Common Terminology Criteria Adverse Events ( CTCAE ) grade 1 time start study treatment exception alopecia . Presence lifethreatening metastatic visceral disease , uncontrolled central nervous system metastatic disease symptomatic pulmonary lymphangitic spread . Any evidence severe uncontrolled systemic disease , include uncontrolled hypertension , active bleeding diatheses , active infection . Unexplained symptomatic endometrial disorder . Uncontrolled symptomatic thyroid dysfunction . Inadequate bone marrow reserve organ function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Ascending Doses</keyword>
	<keyword>Estrogen Receptor Positive</keyword>
	<keyword>Her2 Negative</keyword>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>